presentation by Aegis Biotech at the Cannabis Science Conference by jCanna in Portland OR 2017

1. THC-A based cannabis therapies - healthy cannabis without the high
Adam D. Richardson and Amy Berliner - - - Aegis Biotech, San Diego CA
Abstract
The activity of the human cannabinoid
receptors CB1 and CB2 are modulated by
many of the small molecules in cannabis,
particularly THC, CBD and many terpenes.
The cannabis plant does not produce THC
directly but instead synthesizes the water-
soluble THC-A. THC-A produces many of
the same physiological effects of THC;
however, due to being acidic and water-
soluble, does not cross the blood brain
barrier and does not create psychological
effects. Aegis Biotech is developing THC-A
based products, supplemented with CBD
and specific terpenes, to deliver medicinal
cannabis products for cancer, inflammation
and pain management.
@ADRPHD this poster is available at www.slideshare.net/ADRPHD
Cannabis primarily produces THC-A
- THC-A is the acidic, water-soluble cannabinoid produced by
the plant
- Smoking, vaping and other forms of heat remove the
carboxylic acid from THC-A to produce THC
- THC is lipophilic (fat soluble) which allows it to cross the
blood-brain barrier and activate CB1 receptors in the brain
- Since it remains in the circulating blood stream, THC-A is highly bioavailable and reaches many
tissues and cell types
- Activation of the CB1 or CB2 receptors by THC-A and other cannabis compounds occurs
throughout human tissues, particularly the peripheral nervous system (for pain management),
the gut, and the immune system.
- THC-A extraction does not require heat, increasing our recovery of other beneficial compounds
such as terpenes and CBD
Neurotoxicol Teratol. 2014 Nov-Dec;46:49-56. doi: 10.1016/j.ntt.2014.09.003. Epub 2014 Oct 12.
Streem
Blockchain-based data
collection
Aegis
Cannabis based
medical product
development
CannaHealthcare
Clinically focused
virtual magazine (part
of the CannaInvestor
family)
Jitita Analytical
Metabolism
Receptor targeting and
cell biology